Moderna says new RSV vaccine 84% effective in older adults
Moderna intends to submit the RSV vaccine for regulatory approval in the first half of 2023.
A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020(photo credit: REUTERS/BRIAN SNYDER)Updated: 
